Nutritional Status, Energy and Protein Intakes in Non-Small Cell Lung Cancer Patients Receiving Chemotherapy
Keywords:
nutritional status, malnutrition, non-small cell lung cancer, medical food, chemotherapyAbstract
The pathology of non-small cell lung cancer (NSCLC) and chemotherapy-related adverse reactions may have an effect on nutritional status and cause serious complications. This cross-sectional descriptive study aimed to assess nutritional status, energy, and protein intake as well as the reported chemotherapy-related adverse drug reactions in NSCLC patients at Vongvanich Building, King Chulalongkorn Memorial Hospital during November 2021 and March 2022.
Overall, 30 participants with mean age of 62.5±1.1 years old were included. 86.7% of participants presented with malnutrition and 40% of participants had insufficient dietary protein intake per day. 70% of participants reported the current use of oral nutritional supplements, of which 42.9% were advised by healthcare professionals. 86.7% of patients experienced chemotherapy-related adverse reactions. The highest prevalence reported as anemia, peripheral sensory neuropathy, and insomnia at 46.7%, 36.7%, 33.3% of the participants, respectively.
Patients with non-small cell lung cancer receiving chemotherapy were highly susceptible to malnutrition,
which reported adverse reactions during the treatment period. Therefore, this group of patients should be continuously assessed for their nutritional status and closely monitored the possible adverse events.
References
Goodarzi E, Sohrabivafa M, Adineh HA, Moayed L, Khazaei Z. Geographical distribution global incidence and mortality of lung cancer and its relationship with the human development index (HDI); An ecology study in 2018. World Cancer Res J. 2019;6:e1354.
World health organization international agency for research on cancer (IARC). GLOBOCAN 2020: estimated cancer incidence, mortality, and prevalence worldwide in 2020. [internet]. 2020 [cited 2020 Feb 23]. Available from: https://gco.iarc.fr/today/ data/factsheets/populations/900-world-fact-sheets.pdf.
National cancer institute department of medical services ministry of public health Thailand [internet]. Bangkok: department of medical service; [cited 2020 Nov 2]. Hospital-based cancer registry 2020; [130 pages]. Available from: https://fliphtml5.com/jxrsj/xcqd.
Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94(8):1623-40.
Ettinger DS, Aisner DL, Wood DE, Akerley W, Bauman J, Chang JY, et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. J Natl Compr Canc Netw. 2021;19(3):254-66.
Fujio T, Nakashima K, Naito T, Kobayashi H, Omori S, Wakuda K, et al. Platinum combination chemotherapy is poorly tolerated in malnourished advanced lung cancer patients with poor performance status. Nutr Cancer. 2019;71(5):767-71.
Ravasco P. Nutrition in cancer patients. J Clin Med. 2019;8(8):1211.
Santarpia L, Contaldo F, Pasanisi F. Nutritional screening and early treatment of malnutrition in cancer patients. J Cachexia Sarcopenia Muscle. 2011;2(1):27-35.
Ryan AM, Prado CM, Sullivan ES, Power DG, Daly LE. Effects of weight loss and sarcopenia on response to chemotherapy, quality of life, and survival. Nutrition. 2019;67:110539.
Chavenkijsakol D, Kongjan J, Suwanwattanakul T. Knowledge on medical foods and dietary supplements in cancer patients receiving chemotherapy. [dissertation]. Bangkok, Thailand: Chulalongkorn university; 2017.
Nitichai N, Angkatavanich J, Somlaw N, Voravud N, Lertbutsayanukul C. Validation of the Scored Patient-Generated Subjective Global Assessment (PG-SGA) in Thai setting and association with nutritional parameters in cancer patients. Asian Pac J Cancer Prev. 2019;20(4):1249-55.
US Department of health and human services. National cancer institute. Terminology criteria for adverse events (CTCAE) version 5.0. [Internet]. 2017. [cited 2021 October 2]. Available from: https://ctep.cancer.gov/protocoldevelopment/ electronic_applications/ docs/ctcae_v5_quick_reference_5x7.pdf.
Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017;36(1):11-48.
Sanchez-Lara K, Turcott JG, Juarez E, Guevara P, Núñez-Valencia C, Oñate-Ocaña LF et al. Association of nutrition parameters including bioelectrical impedance and systemic inflammatory response with quality of life and prognosis in patiens with advanced non-small-cell lung cancer: a prospective study. Nutrition and Cancer. 2012;64(4):526-34.
Muscaritoli M, Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, et al. ESPEN practical guideline: Clinical Nutrition in cancer. Clin Nutr. 2021;40(5):2898-913.
Mohan A, Poulose R, Kulshreshtha I, Chautani A, Madan K, Hadda V, et al. High prevalence of malnutrition and deranged relationship between energy demands and food intake in advanced non-small cell lungcancer. Eur J Cancer Care (Engl). 2017;26(4):e12503.
Ulmann G, Jouinot A, Tlemsani C, Curis E, Kousignian I, Neveux N, et al. Lean body mass and endocrine status but not age are determinants of resting energy expenditure in patients with non-small cell lung cancer. Ann Nutr Metab. 2019;75(4):223-30.
Trestini I, Sperduti I, Sposito M, Kadrija D, Drudi A, Avancini A, et al. Evaluation of nutritional status in non-small-cell lung cancer: screening, assessment and correlation with treatment outcome. ESMO open. 2020;5(3):e000689.
Ge T, Lin T, Yang J, Wang M. Nutritional status and related factors of patients with advanced lung cancer in northern China: a retrospective study. Cancer Manag Res. 2019;11:2225-31.
Rungruang C, Siritientong T. Effects of chemotherapy on nutrition in cancer patients. Thai JPEN. 2019;2:57-66.
Park SH, Jeong SH, Kyung SY, Lim Y-H, An CH, Lee SP, et al. Gemictabine plus carboplatin in patients with advanced non-small cell lung cancer. Med Oncol. 2005;22(4):359-66.
Yumuk PF, Turhal NS, Gumus M, Hatabay NF, Turken O, Ozkan A, et al. Results of paclitaxel (day 1 and 8) and carboplatin given on every three weeks in advanced (stage III-IV) non-small cell lung cancer. BMC cancer. 2005;5(1):1-7.
Mahalingam D, Nemunaitis JJ, Malik L, Sarantopoulos J, Weitman S, Sankhala K, et al. Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014;74(6):1241-50.
Kim YS, Cho EK, Woo HS, Hong J, Ahn HK, Park I, et al. Randomized phase II study of pemetrexed versus gefitinib in previously treated patients with advanced non-small cell lung cancer. Cancer Res Treat. 2016;48(1):80-7.
Del Ferraro C, Grant M, Koczywas M, Dorr-Uyemura LA. Management of anorexia-cachexia in late-stage lung cancer patients. J Hosp Palliat Nurs. 2012;14(6): 10.1097/NJH.0b013e31825f3470.
Dewan K. Chemotherapy and dysphagia: the good, the bad, the ugly. Curr Opin Otolaryngol Head Neck Surg. 2020;28(6):385-91.
Pulito C, Cristaudo A, Porta CL, Zapperi S, Blandino G, Morrone A, et al. Oral mucositis: the hidden side of cancer therapy. J Exp Clin Cancer Res. 2020;39(1):1-15.
Peterson D, Boers-Doets C, Bensadoun R, Herrstedt J. Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2015;26:v139-v51.
Sevryugin O, Kasvis P, Vigano M, Vigano A. Taste and smell disturbances in cancer patients: a scoping review of available treatments. Support Care Cancer. 2021;29(1):49-66.
Amézaga J, Alfaro B, Ríos Y, Larraioz A, Ugartemendia G, Urruticoechea A, et al. Assessing taste and smell alterations in cancer patients undergoing chemotherapy according to treatment. Support Care Cancer. 2018;26(12):4077-86.
Waqar SN, Mann J, Baggstrom MQ, Waqar MA, Chitneni P, Williams K, et al. Delayed nausea and vomiting from carboplatin doublet chemotherapy. Acta Oncol. 2016;55(6):700-4.
Ponticelli E, Clari M, Frigerio S, De Clemente A, Bergese I, Scavino E, et al. Dysgeusia and health-related quality of life of cancer patients receiving chemotherapy: A cross-sectional study. Eur J Cancer Care (Engl). 2017;26(2):e12633.
Spencer AS, da Silva Dias D, Capelas ML, Pimentel F, Santos T, Neves PM, et al. Managing severe dysgeusia and dysosmia in lung cancer patients: A systematic scoping review. Front Oncol. 2021;11:774081.
Leijen S, van Geel RM, Pavlick AC, Tibes R, Rosen L, Razak ARA, et al. Phase I study evaluating WEE1 inhibitor AZD1775 as monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. J Clin Oncol. 2016;34(36):4371-80.
McQuade RM, Stojanovska V, Abalo R, Bornstein JC, Nurgali K. Chemotherapy-induced constipation and diarrhea: pathophysiology, current and emerging treatments. Front Pharmacol. 2016;7:414.
Sanz EA, Abilés J, Siles GM. Ruíz FR, Goitia BT, Domínguez AR. Evaluation of a protocol to detect malnutrition and provide nutritional care for cancer patients undergoing chemotherapy. Sci Rep. 2020;10(1):21186.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Thai JPEN วารสารโภชนบำบัด
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The content and information in the articles published in Thai JPEN วารสารโภชนบำบัด, are the opinions and responsibility of the authors directly. The editorial team is not obliged to agree or take any responsibility.
All articles, content, figures, etc. that have been published in Thai JPEN วารสารโภชนบำบัด are the copyright of Thai JPEN วารสารโภชนบำบัด. If any person or organization require distribution of all or any part of them, please send the request for the written permission from Thai JPEN วารสารโภชนบำบัด only.
